T. Rowe Price Investment Management
FATE icon

T. Rowe Price Investment Management’s Fate Therapeutics FATE Stock Holding History

T. Rowe Price Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-104,938
Closed -$500K – 577
2023
Q2 		$500K Buy
104,938
+4,858
+5% +$26.8K ﹤0.01% 546
2023
Q1 		$571K Sell
100,080
-333,789
-77% -$2.01M ﹤0.01% 542
2022
Q4 		$4.38M Buy
433,869
+27,725
+7% +$521K ﹤0.01% 527
2022
Q3 		$9.1M Buy
+406,144
New +$11.7M 0.01% 504

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management's FATE Position: Q3 2023 in Review

T. Rowe Price Investment Management sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 104,938 shares — an estimated $500K sold.

T. Rowe Price Investment Management first reported a position in FATE in Q3 2022 and held it in 4 quarters. The position peaked at $9.1M in Q3 2022. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • T. Rowe Price Investment Management reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 104,938 Fate Therapeutics shares in Q3 2023, an estimated $500K.
  • T. Rowe Price Investment Management first reported a position in Fate Therapeutics in Q3 2022 and held it in 4 quarters.
  • T. Rowe Price Investment Management's Fate Therapeutics position peaked at $9.1M in Q3 2022.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on T. Rowe Price Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.